SCHEMBL1397423

SCHEMBL1397423

NC(=O)c1ccc(N2CCCC2)c(C(F)(F)F)c1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.55
GAA P10253 1/20 0.55
PKM P14618 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
TAAR1 Q96RJ0 1/20 0.50
CYP3A4 P08684 2/20 0.49
CYP2C19 P33261 2/20 0.49
SLC9A1 P19634 1/20 0.48
KDM4E B2RXH2 2/20 0.48
HSD17B10 Q99714 2/20 0.48
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.48
THRB P10828 1/20 0.48
ALOX15 P16050 1/20 0.48
GFER P55789 1/20 0.48
YWHAG P61981 1/20 0.48
KMT2A Q03164 1/20 0.48
HSD11B1 P28845 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16380654 0.87 KDM4E (0.66) ALDH1A1CYP3A4CYP2C19SLC9A1KDM4E
SCHEMBL2709426 0.87 SMN1; SMN2 (0.56) ALDH1A1CYP3A4CYP2C19SLC9A1KDM4E
SCHEMBL3526351 0.86 TTR (0.59) GAAL3MBTL1TAAR1KDM4EHSD17B10
SCHEMBL8261930 0.86 CTPS1 (0.62) ALDH1A1GAASLC9A1KDM4EHSD17B10
SCHEMBL3309679 0.86 KDM4E (0.47) ALDH1A1GAAPKML3MBTL1CYP3A4
SCHEMBL3309681 0.86 ALDH1A1 (0.47) ALDH1A1GAAPKML3MBTL1TAAR1
SCHEMBL2776207 0.85 KDM4E (0.61) GAAL3MBTL1TAAR1KDM4EHSD17B10
SCHEMBL17386600 0.85 TAAR1 (0.56) TAAR1MAPT
SCHEMBL30949180 0.85 TAAR1 (0.50) ALDH1A1TAAR1MAPT
SCHEMBL3643489 0.85 KDM4E (0.61) GAAL3MBTL1TAAR1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190834-B1 PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER HOFFMANN LA ROCHE (CH) 2011-03-02 EP claimed
EP-2190834-A1 PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER F. Hoffmann-Roche AG (CH) 2010-06-02 EP claimed
EP-2065380-A1 Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer F.HOFFMANN-LA ROCHE AG (CH) 2009-06-03 EP claimed
WO-2009024332-A1 PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2009-02-26 WO claimed
EP-2190834-A1 PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER F. Hoffmann-Roche AG (CH) 2010-06-02 EP disclosed
EP-2065380-A1 Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer F.HOFFMANN-LA ROCHE AG (CH) 2009-06-03 EP disclosed
WO-2009024332-A1 PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2009-02-26 WO disclosed